loading page

Use of dornase alfa in cystic fibrosis: an Audit of Italian specialists
  • +3
  • Sonia Volpi,
  • Vincenzo Carnovale,
  • Carla Colombo,
  • Valeria Raia,
  • Francesco Blasi,
  • Giovanni Pappagallo
Sonia Volpi
Azienda Ospedaliera Universitaria Integrata Verona

Corresponding Author:[email protected]

Author Profile
Vincenzo Carnovale
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Cystic Fibrosis Center, Milan, Italy
Author Profile
Carla Colombo
University "Federico II", Naples, Italy
Author Profile
Valeria Raia
University of Naples Federico II
Author Profile
Francesco Blasi
IRCCS Cà Granda Ospedale Maggiore Policlinico Milano
Author Profile
Giovanni Pappagallo
Private Epidemiologist
Author Profile


Background: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient’s lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. Method: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. Results: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. Conclusions: Modified Delphi method was used to define the most appropriate use of dornase alfa in routine CF to improve lung function and long-term outcomes in patients, in agreement with international guidelines on CF management.